Effects of high-density lipoproteins on pancreatic β-cell insulin secretion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 8, 2010, Pages 1642-1648

  Fryirs, Michelle A ^a   Barter, Philip J ^a,c   Appavoo, Mathiyalagan ^d   Tuch, Bernard E ^d   Tabet, Fatiha ^a   Heather, Alison K ^b   Rye, Kerry Anne ^a,c,e  

^a Lipid Research Group   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c University of Sydney   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

apolipoproteins; ATP binding cassette transporter; cells; diabetes mellitus; lipoproteins

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CALCIUM; HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GLUCOSE INTAKE; GLUCOSE METABOLISM; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM; CELL LINE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIAZOXIDE; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; KATP CHANNELS; KINETICS; LIPOPROTEINS; LIPOPROTEINS, HDL; MICE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS B; UP-REGULATION;

EID: 77955170942     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.207373     Document Type: Article

References (19)

1. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51:703-713.
2. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus\a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777-783.
3. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218.
4. UKPDS Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
6. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328-2338.
7. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119: 2103-2111.
8. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-347.
9. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278: 18368-18375.
10. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia. 2007;50:1304-1314.
11. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, von Eckardstein A. Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009; 150:4521-4530.
12. Ishikawa M, Iwasaki Y, Yatoh S, Kato T, Kumadaki S, Inoue N, Yamamoto T, Matsuzaka T, Nakagawa Y, Yahagi N, Kobayashi K, Takahashi A, Yamada N, Shimano H. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J Lipid Res. 2008;49:2524-2534.
13. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem. 2003;278:47890-47897.
14. Ashcroft FM, Proks P, Smith PA, Ammala C, Bokvist K, Rorsman P. Stimulus-secretion coupling in pancreatic beta cells. J Cell Biochem. 1994;55(suppl):54-65.
15. Ammala C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature. 1993;363: 356-358.
16. Haidar B, Denis M, Marcil M, Krimbou L, Genest J Jr. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem. 2004;279:9963-9969.
17. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apoli-poproteins. J Biol Chem. 2005;280:30150-30157.
18. Mulya A, Lee JY, Gebre AK, Boudyguina EY, Chung SK, Smith TL, Colvin PL, Jiang XC, Parks JS. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res. 2008;49: 2390-2401.
19. Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343-1372.